Current Report No. 7/2026 – Notice of Convening the Annual General Meeting of Celon Pharma S.A. on June 24, 2026, Together with Draft Resolutions

Legal basis: Article 56(1)(2) of the Public Offering Act – Current and Periodic Information

Report content:

The Management Board of Celon Pharma S.A. (the “Company”), acting pursuant to Articles 395 §1, 399 §1, 402(1) and 402(2) of the Polish Commercial Companies Code (the “CCC”), hereby convenes the Annual General Meeting to be held on June 24, 2026, at 11:00 a.m. at the Company’s Research and Development Centre in Kazuń Nowy, ul. Marymoncka 15.

Proposed agenda:

  1. Opening of the Annual General Meeting.
  2. Election of the Chairperson of the Annual General Meeting.
  3. Confirmation that the Annual General Meeting has been duly convened and is capable of adopting resolutions.
  4. Election of the Ballot Counting Committee of the Annual General Meeting.
  5. Adoption of the agenda of the Annual General Meeting.
  6. Consideration of the Management Board’s Report on the activities of the Company and the Capital Group for the financial year 2025 and adoption of a resolution approving such report.
  7. Consideration of the Company’s separate financial statements for the financial year 2025 and adoption of a resolution approving such financial statements.
  8. Consideration of the consolidated financial statements of the Capital Group for the financial year 2025 and adoption of a resolution approving such financial statements.
  9. Adoption of a resolution regarding the Management Board’s recommendation concerning the coverage of the loss and the non-payment of a dividend for the financial year 2025.
  10. Consideration of the Supervisory Board Report for the financial year 2025 prepared in accordance with Article 382 §3(3) of the CCC and taking into account the requirements of the Best Practice for GPW Listed Companies 2021, and adoption of a resolution approving such report.
  11. Adoption of a resolution expressing an opinion on the “Report on the Remuneration of the Members of the Management Board and the Supervisory Board of Celon Pharma S.A. for the period from January 1, 2025 to December 31, 2025.”
  12. Granting discharge to the members of the Management Board in respect of the performance of their duties in 2025.
  13. Granting discharge to the members of the Supervisory Board in respect of the performance of their duties in 2025.
  14. Appointment of members of the Supervisory Board of Celon Pharma S.A. for a new term of office.
  15. Miscellaneous motions.
  16. Closing of the General Meeting.